The mevalonate pathway is a core biochemical process, crucial for the generation of cholesterol and other key metabolic end products. The rate-limiting enzyme of the mevalonate pathway, hydroxymethylglutaryl coenzyme A reductase (HMGCR), is safely and effectively targeted by the statin family of inhibitors to treat hypercholesterolemia. The anticancer activity of statins has also been widely reported, yet the tumor-selective mechanisms that mediate these antiproliferative effects remain largely unclear. The importance of altered metabolism in the context of tumorigenesis has received renewed attention as metabolic changes entwined with the molecular hallmarks of cancer have been elucidated. Although several metabolic pathways have been linked to cancer progression and etiology, it was only recently that HMGCR and the mevalonate pathway were also shown to have a distinct role in cellular transformation. In this review, we chart the historical progression of statins from cholesterol-lowering blockbusters to anticancer agents with imminent potential, and further discuss an emerging role for HMGCR and the mevalonate pathway in the metabolic reprogramming of cancer.
INTRODUCTION
The statin family of inhibitors has made substantial impact on human health. Originally developed as cholesterol-lowering agents that target hydroxymethylglutaryl coenzyme A reductase (HMGCR), statins are among the most therapeutically effective and financially successful pharmaceuticals created. Now, as patent protection has ended, or nears its end, they are on the verge of making a new and lasting impact on a very different disease: cancer. Though statins have been investigated as potential anticancer agents for at least 20 years, new data has emerged to provide concrete insight into how to realistically navigate their transition to patient care. In this review, we revisit the origin of statins and follow the path they have taken toward anticancer therapy. We further detail evidence that shows HMGCR can have a vital role in the metabolic shift that occurs in many cancer cells and highlight the manner in which statins may best be applied to target tumor cell metabolism in clinical practice.
THE CIRCUITOUS PATH FROM CHOLESTEROL TO CANCER
Where it all began: clogged arteries Statins entered the pharmaceutical landscape about 30 years ago as a treatment for hypercholesterolemia. 1 --3 Today, they are among the most frequently prescribed drugs worldwide and represent a class of blockbuster agents that have brought significant benefit to patients' lives. But the statin story truly began 4100 years ago ( Figure 1 ) when it was observed that the artery walls of patients dying from occlusive vascular disease and myocardial infarction were frequently thick and irregular. Cholesterol was later identified as the cause of these irregularities. Despite these observations, physicians were skeptical of a causal link between cholesterol and coronary heart disease (CHD) because most CHD patients presented with relatively normal plasma cholesterol levels. 4, 5 It was not until the 1950s that the Framingham study and others established a convincing correlation between high plasma cholesterol and CHD mortality ( Figure 1 ). 5, 6 Later research demonstrated that CHD mortality is specifically linked to low-density lipoprotein (LDL)-cholesterol, whereas high-density lipoprotein-cholesterol is inversely correlated with CHD mortality. 5, 7 Because it had not been shown convincingly that lowering cholesterol provided clinical benefit, this lipid hypothesis was considered controversial for many years.
The birth of a blockbuster In 1971, Endo et al. 8 initiated a search for microbial metabolites capable of inhibiting HMGCR, the rate-limiting enzyme of the mevalonate pathway, with the hope that suppression of de novo cholesterol synthesis would result in decreased plasma cholesterol in humans. The result of these studies was a potent HMGCR inhibitor called mevastatin (formerly ML-236B or compactin; Figure 1 ). Subsequent studies demonstrated that the drug specifically lowered LDL-cholesterol in experimental animals and humans. 9 --11 Analogs of mevastatin were soon developed, and lovastatin, simvastatin and pravastatin were approved for clinical use and on the market by 1990. 2, 12 Owing to skepticism regarding the benefits of lowering LDLcholesterol, statins were initially not widely used. However, using quantitative angiography and ultrasound, they were eventually shown to slow the progression of atherosclerotic lesions. 13 --19 In 1994, results of the Scandinavian Simvastatin Survival Study (often referred to as the '4S trial') marked the first unequivocal evidence of statin efficacy (Figure 1) . 20 Over 4000 patients with CHD, high total plasma cholesterol and on a lipid-lowering diet were randomized to receive either simvastatin or placebo for 5 years. The highly significant reduction in all-cause mortality was largely due to a reduced number of coronary deaths, major coronary events and revascularization procedures. Because there was also no evidence showing increases in non-cardiovascular mortality, violent deaths or cancer, these results demonstrated that lowering cholesterol was a safe and effective strategy for reducing CHD. 21 These results were confirmed in several other large-scale studies, 22 --26 and quickly placed statins among the most successful pharmaceuticals to date.
An elegant mechanism of action HMGCR and the mevalonate pathway received considerable attention 20 --30 years ago through the Nobel Prize-winning efforts of Drs Goldstein and Brown ( Figure 1 ). It is primarily through their work that we now understand how statins mediate their cholesterol-lowering effects.
Cellular cholesterol is obtained in two ways. It can either be derived by receptor-mediated uptake of LDL-cholesterol from blood plasma, or be synthesized from acetyl-coenzyme A (CoA) by the activity of HMGCR. Drs Goldstein and Brown showed that inhibition of HMGCR triggers a robust homeostatic feedback response in cells attempting to upregulate and restore the mevalonate pathway (Figure 2 ), reviewed elsewhere. 27, 28 Briefly, when intracellular sterol levels are high, endoplasmic reticulumtethered cytoplasmic transcription factors, known as sterol regulatory element-binding proteins (SREBPs), are held in a latent form by SREBP cleavage-activating proteins (SCAP) and proteins encoded by the insulin-induced genes (INSIGs)-1 and -2. When statins inhibit HMGCR activity, intracellular end products of the mevalonate pathway are depleted. As sterol levels decrease, they no longer bind SCAP, thereby inducing a conformational change that allows for the SCAP --SREBP complex to be shuttled to the golgi. Successive cleavages of SREBP by golgi-resident site-1 and -2 proteases result in the release of activated SREBP from the membrane. The transcription factors are then free to be translocated to the nucleus where they bind DNA at promoter regions containing sterol response elements. This induces the transcription of several key target genes, including HMGCR and the LDL receptor. Increased levels of LDL receptor at the cell surface internalize LDL-cholesterol, thus lowering circulating cholesterol. It is this extraordinary feedback mechanism that has been exploited by statins to control hypercholesterolemia with profound success. 29 While the liver is the primary site of statin action in terms of lowering plasma cholesterol, the same feedback response is seen in other normal cells of the body. 30 Revealing the anticancer potential of statins The antiproliferative activity of statins was demonstrated about 20 years ago (Figure 1 ). Indeed, it has long been known that statins can trigger G1 arrest in some transformed cells in culture. 31, 32 In breast cancer cells, for instance, the arrest response
Year

Early 1900s
Awareness of thick and irregular artery walls in patients with occlusive vascular disease (4, 5) 
1924
Discovery that tumo cells consume large amounts of glucose and convert it into lactate; birth of the Warburg phenomenon and an understanding of the importance of altered metabolism in cancer (119) 1950s
Framingham study establishes link between high plasma cholesterol and CHD mortality (5, 6) Hypothesis that losing regulation of the mevalonate pathway may be a causal feature of cancer (106) 1970s 1970 Brown and Goldstein determine central role of hepatic LDLR in determining plasma concentrations of LDL cholesterol (27, 28) 
Mid 1970s
Discovery of first HMGCR inhibitor (ML-236B/compactin/mevastatin); birth of the statin class of drugs (8) Brown and Goldstein awarded Nobel Prize for their work First statin becomes available (lovastatin) (2, 12) Three statins on the market (lovastatin, simvastatin, pravastatin) (2, 12) Appreciation of the anti-proliferative potential of statins (31, 32) is mediated by modulation of activity, expression and/or distribution of cyclin-dependent kinase 2, p21 and p27. 33 --35 As a mevalonate-reversible process, statin-induced growth arrest is achieved specifically by inhibition of HMGCR. Subsequent research on a plethora of transformed cells in culture has shown that the antiproliferative effect of statins is largely tumor selective. 36 --51 This suggests that the corresponding cancers might be susceptible to statin treatment in vivo. Importantly, the antiproliferative effects of statins are frequently mediated though an induction of apoptosis, indicating that they may also have the potential to cure rather than only stabilize disease. For example, our lab and others have shown that acute myeloid leukemia (AML) cells from both primary tumors and established cell lines undergo apoptosis when treated with lovastatin, whereas normal myeloid progenitor cells retain their full proliferative potential. 37, 38 Statins have been shown to possess anticancer activity in a wide range of in vitro and in vivo pre-clinical models, including both liquid tumors such as leukemia and myeloma, and solid tumors such as breast, prostate, colorectal, lung, pancreas, ovarian, cervical and head & neck cancers, reviewed extensively elsewhere. 3,52 --54 The promising preclinical results ultimately prompted 18 reported phase I and I/II clinical trials. 55 --72 Although tumor growth has not always been the primary end point, stable disease and partial or complete remissions were evident in some, but not all, patients. 55 --60,70,71 In a case-study report, we have also shown that low doses (twice what is typically used to lower cholesterol) administered for prolonged duration was associated with the control of tumor burden and minimal side effects. 73 Finally, more recent trials have also shown that low, cholesterol lowering-like doses of statins can reduce proliferation and increase apoptosis of tumor cells in patients. 61 Taken together, the potential for further success has motivated research at the molecular level to determine how best to use statins as anticancer agents.
Epidemiological support for the anticancer activity of statins The capacity for statins to inhibit HMGCR is an appealing strategy for targeting certain tumor types, particularly because of familiarity with their pharmacodynamic and safety parameters. As statins have been prescribed to lower the cholesterol of millions of patients for many years, there is a wealth of data that can be mined for evidence of whether statin use is associated with cancer incidence, recurrence or severity. In fact, the past several years have seen a vast increase in epidemiological analyses addressing these questions.
Overall, the results have been mixed and largely dependent on both the type of tumor in question and the particular statin that was used. Statin users have been reported to have reductions of cancer incidence by up to about 50%, 74 --79 lower grade and stage of tumor, 80 and a decreased risk of recurrence. 81, 82 By contrast, other studies found no association between statin use and cancer risk. 83 --85 These latter studies, however, have also been criticized for short follow-up times, and lack of consideration for the type of statin as well tumor subtype. 78, 86, 87 When these variables are accounted for, certain statins do appear to confer some degree of protection against cancer incidence or progression. 75, 80, 81, 88 Most importantly, several prospective clinical trials addressing whether statins decrease cancer incidence are now underway. 89 The immunomodulatory nature of statins Statins are also known to have a variety of immunomodulatory effects. There has been some degree of contradiction, as it has been suggested that this effect could both inhibit and accelerate transformation. This is particularly true in the transplant setting, as administration of immunosuppression is recognized as a key cause of cancer following transplantation. 90 The impact of statins on immunological function is enormous and has been extensively reviewed elsewhere. 91, 92 Briefly, however, these effects include: the induction of apoptosis in CD4 þ T cells; 93 downregulation of chemokine secretion and receptor expression; 94, 95 suppressed expression of numerous adhesion molecules on organ tissue and circulating cells; 90, 96, 97 alteration of cytokine and metalloproteinase expression; 98 modulation of natural killer cell cytotoxic activity. 99, 100 More study is required to fully understand how the immunomodulatory effects of statins ultimately impact human cancers.
THE THERAPEUTIC INDEX FOR STATIN USE IN CANCER
The nature of statin tumor-selectivity Despite the mounting body of evidence demonstrating a degree of tumor-selective anticancer activity, the underlying therapeutic index of statins has been poorly understood. This is especially confounding as statins are also known to have effects on certain Figure 2 . Inhibition of HMGCR triggers a robust homeostatic feedback response in normal cells. HMGCR in the cell is normally able to maintain the levels of mevalonate end products, whereas SREBP is held latent in the endoplasmic reticulum (see text for additional detail; panel 1). When statins enter a normal cell and block HMGCR activity, intracellular mevalonate pathway end products are eventually depleted (panel 2). The reduction of sterol levels, especially cholesterol, activates cytoplasmic transcription factors called SREBPs, which translocate to the nucleus and bind DNA at promoter regions containing sterol response elements (SREs). Here, SREBPs drive transcription of target genes including HMGCR itself and the LDL receptor (LDLR) (panel 3). Increased levels of LDLR at the cell surface internalize LDL-cholesterol, thus lowering the amount that is free to circulate in serum. Once the statin has been cleared, the cell is able to reinstate the intracellular mevalonate pathway end products (panel 4).
normal cells. For example, myopathy is a rare but potentially dangerous side effect of statin use that is likely a result of the induction of apoptosis in skeletal muscle cells. 101 At least in some cases, however, this appears to be controllable by co-administering coenzyme Q10. 102 This serves as a clear reminder that the mevalonate pathway is active in both normal and tumor cells, and makes the tumor selectivity of statins difficult to conceptualize. Recently, however, we gained a glimpse into a molecular rationale that explains how statins may drive tumor-selective killing.
The mevalonate pathway as a driver of transformation Recent work in our lab has defined a distinct role for HMGCR and the mevalonate pathway in oncogenesis. Specifically, we showed that dysregulation of the mevalonate pathway can make a causal contribution to transformation and that HMGCR is a candidate metabolic oncogene (Figure 1) . 103 When overexpressed in a deregulated state, HMGCR increased anchorage-independent growth of transformed cells in soft agar as well as the growth of xenografts, prompting us to address its impact on less transformed cells. Deregulated HMGCR was also able to potentiate anchorage-independent growth of an immortalized, non-transformed cell line and to promote the formation of myeloid colonies from normal hematopoietic progenitors. Most notably, in a classic oncogene assay, HMGCR cooperated with RAS to promote the transformation of wild-type primary mouse embryonic fibroblasts. In addition to this functional evidence, we showed that high messenger RNA levels of five mevalonate pathway genes, including HMGCR, correlated with poor prognosis in breast cancer patients.
Taken together, these results suggest that HMGCR and the mevalonate pathway are subject to dysregulation in at least a subset of cancers; they may be integral components of the global metabolic transformation of tumor cells. 103 Interestingly, and to the best of our knowledge, no other fundamentally metabolic genes have been shown to directly promote transformation in classic oncogene cooperativity assays. The manner by which HMGCR and the mevalonate pathway become dysregulated is not yet well defined, nor is it known how this dysregulation promotes tumorigenesis. However, it is known that HMGCR and the mevalonate pathway are tightly controlled at many levels, 1 providing ample opportunity for deregulation to occur in the course of transformation (Figure 3 ).
Searching for biomarkers within the mevalonate pathway One speculation to be made from the oncogenic potential of HMGCR is that tumors harboring a dysregulated mevalonate pathway may also be sensitive to the anticancer activity of statins. This hypothesis follows the general tenets of oncogene addiction and may provide some insight into which patients should be treated with statins. Mixed results from early clinical trials with statins indicate that some tumors may be more sensitive to statins than others. Unfortunately, few trials have specifically enriched for subsets of patients whose tumors are preferentially statinsensitive. Thus, identifying a biological indicator of sensitivity to the anticancer activity of statins could have enormous impact on future statin use in clinical trials and beyond.
Following an analysis of multiple myeloma cell lines for their response to statin exposure, we recently identified subsets of statin-sensitive and -insensitive cells. 36 This afforded us an opportunity to evaluate distinct statin responses within a single tumor type and to determine the effects of statins at the molecular level. 36, 39 We therefore conducted messenger RNA microarray analysis of cells treated with vehicle control or lovastatin, and harvested at a time point prior to apoptosis to capture the mechanism of response. Molecular differences between the two cohorts were striking in both basal and statinexposed conditions. Interestingly, insensitive cells showed a robust sterol feedback response reminiscent of normal cells with an immediate upregulation of many SREBP target genes, including HMGCR and 3-hydroxy-3-methylglutaryl-CoA synthase 1.
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Though the homeostatic goal of the sterol feedback response is to reinstate the mevalonate pathway, sensitive cells showed only a modest feedback response. Such a weak response may indicate that the cells had either lost checkpoint controls keeping the pathway intact, or that the pathway was dysregulated and a decrease in HMGCR activity was not detected by the usual intracellular sensors, possibly SCAP and the INSIGs (Figure 4 ). It appears as though the sterol feedback response may serve as a protective measure, ensuring that a normal cell, or statininsensitive tumor cell, is protected from the anticancer action of statins. By contrast, one group has provided evidence of an intact sterol feedback response in AML cells, 57, 104, 105 suggesting that the loss of this feedback loop may not be a universal phenomenon across all statin-sensitive tumor types.
We also demonstrated that several mevalonate pathway genes exhibited distinct patterns of expression between the insensitive and sensitive myeloma cohorts at the basal level. 39 It will therefore be of great interest to uncover the molecular differences that underlie these differential expression patterns and to assess their functional roles in regulating the response.
Taken together, it appears that dysregulation of the mevalonate pathway may, in some cases, be both a promoter of transformation and an indicator of statin sensitivity. We now have the opportunity to further explore these results with the goal of developing molecular diagnostic tools to predict statin-sensitive tumors and advance statins to anticancer therapy in a clear and rational manner.
Interplay between the mevalonate pathway, cholesterol synthesis and cancer The notion that cholesterol and the mevalonate pathway have a role in cancer etiology and progression was initially suggested years ago. By demonstrating that hepatic tumors lost regulatory control of the mevalonate pathway, it was hypothesized that deleting this feedback control may be a general, and possibly causal, feature of malignancy (Figure 1) . 106 Before the field of tumor cell metabolism received its recent revival, it had also been proposed that an increased demand for cholesterol was an inherent metabolic change in tumor cells that could be exploited Thus far, a deregulated HMGCR is the only fundamentally metabolic gene to directly promote transformation in a classic oncogene cooperativity assay. This suggests that dysregulation of the mevalonate pathway may have sufficient oncogenic potential to drive tumorigenesis. HMGCR and the mevalonate pathway could become dysregulated by a number of mechanisms, some of which are shown here. There could be as yet unidentified activating events at the genomic level (blue), alterations to the transcription, translation, or activity of HMGCR (green) or activations of upstream pathways and regulators (yellow).
in a prophylactic and therapeutic manner. 107 With more modern methodology, transcriptional profiling has also shown that lipid metabolism genes are central to transformation and are upregulated in cancer cells. 108 In addition to its role in cancer cell growth, cholesterol may also mediate sensitivity to chemotherapy. It has been shown, for example, that cholesterol levels are abnormally high in many AML cells exposed to chemotherapy in vitro. 104, 105 Blocking this cholesterol response was further shown to selectively sensitize AML cells to therapeutics, suggesting that cholesterol synthesis inhibitors may improve the efficacy of standard regimens used to treat leukemia. 105 Apoptosis can be inhibited by both cholesterol and decreases in membrane fluidity in some cells, suggesting that high mitochondrial cholesterol content can contribute to chemotherapeutic resistance. 109 Finally, there are also indications that high levels of serum or dietary cholesterol may be associated with increased cancer risk. 110, 111 As was noted earlier, cellular cholesterol is obtained either by receptor-mediated uptake of LDL-cholesterol from blood plasma, or by de novo synthesis as part of the mevalonate pathway. It has long been known that many cancer patients present with striking hypocholesterolemia, 112 likely as a result of deregulated LDL receptor expression and activity. Some tumors have also been shown to either have deficient feedback control, or elevated expression and activity, of HMGCR. 113, 114 Recently, HMGCR expression has been associated with a 'molecular apocrine' subset of breast tumors by gene expression profiling 115 and immunohistochemical analysis, 116 suggesting HMGCR may either contribute to, or serve as a marker for, the development of certain subtypes of cancer. In a different setting, exogenous mevalonate delivered to the tumors of a murine model of cancer also resulted in increased proliferation and more aggressive disease. 117 Finally, work on a MYC-driven model of hepatocellular carcinoma further showed that supplementation with mevalonate resulted in increased tumor growth. 118 Taken together, a complex interplay between cancer and the mevalonate pathway is indicated. These data are strongly supportive of the newly identified role HMGCR has in driving transformation, and suggests that some tumors depend on mevalonate for their continued growth and survival.
The mevalonate pathway is regulated by tumor cell metabolism Though new discoveries have rekindled interest in the field of tumor cell metabolism, the first observation of fundamental differences between normal and tumor cells were made by Otto Warburg in 1924. In his early work, Warburg demonstrated that tumor cells consume disproportionately large amounts of glucose, converting it into lactate. 119 Indeed, the Warburg phenomenon has come to be defined as being the preferential use of glycoloysis for many tumor cells to derive most of their energy. This is
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Statin-insensitive tumor cell Figure 4 . Model for deficient statin-induced sterol feedback in statin-sensitive tumor cells. When exposed to statins, some statin-insensitive tumor cells exhibit a robust sterol feedback response similar to normal cells (panels 3a and 4a). In these cells, many SREBP target genes, including HMGCR, are immediately upregulated, demonstrating their feedback response is intact and possibly defines a protective response from the anticancer effect of statins. Conversely, some statin-sensitive tumor cells show only a modest or deficient feedback response, suggesting these cells may have either lost their checkpoint controls to keep the pathway intact, or that the pathway is dysregulated and unable to detect a decrease in HMGCR activity (panels 3b and 4b).
particularly noteworthy under conditions of high oxygen, when a normal cell would typically make use of aerobic cellular respiration.
But what advantage would a tumor cell gain through increased dependence on aerobic glycolysis, particularly given its comparatively less efficient energy production? For one, it allows the cell to be dependent on one of its most easily accessible nutrients, glucose, to generate vast amounts of energy. Furthermore, glucose catabolism can also serve as a carbon source to provide cells with intermediates required for the biosynthesis of nucleic acids, amino acids and lipids. 120 --124 For example, as it enters an abbreviated citric acid cycle in the mitochondria, glycolysisderived pyruvate is converted to citrate. This citrate is then exported back to the cytoplasm of the cell where it is converted into oxaloacetate and acetyl-CoA by the action of adenosine triphosphate citrate lyase (ACL). One possible fate for the acetylCoA generated by ACL is to be incorporated into mevalonate through the activity of HMGCR. An alternative route involves the incorporation of acetyl-CoA into lipids by fatty acid synthase (FAS) and into phospholipids by the activity of several enzymes including choline kinase. Remarkably, ACL, FAS and choline kinase have all been shown to be induced or upregulated in tumor cells and to have key roles in their growth and/or survival. 125 --127 It will be interesting to determine whether these genes can drive transformation in a fashion similar to HMGCR and be targeted using similar anticancer strategies.
In a recent update to their seminal review on the hallmarks of cancer, Hanahan and Weinberg describe reprogrammed tumor cell metabolism as an emerging hallmark of cancer. 128 They posit that aerobic glycolysis may simply be a phenotype programmed by proliferation-inducing oncogenes such as MYC and RAS, but also recognize that gain-of-function mutations to the metabolic isocitrate dehydrogenase 1/2 enzymes in glioma and leukemia may be clonally selected for their ability to alter the metabolic state of a cell. Though the field is still evolving, they conclude that reprogrammed tumor cell metabolism has evident importance in transformation, and that further research will determine whether it is functionally independent from the core hallmarks of cancer.
A host of molecular alterations, including both the activation of oncogenes and loss of tumor suppressors, are thought to underlie the metabolic shift a tumor cell undergoes toward aerobic glycolysis. In fact, glycolytic genes are amongst the most frequently deregulated in cancer. 129 Glycolysis and the metabolic transformation of a cell are frequently supported by the activation of the hypoxia-inducible factor (HIF)-1. Under hypoxic conditions, HIF-1 is stabilized, binds DNA and modulates transcription of its glycolytic target genes. 130 The activation of many oncogenes and loss-of-function of several tumor suppressors can all result in the stabilization or activation of HIF-1. 130 It was also recently determined that HMGCR is regulated through the transcriptional activity of HIF-1, 131 illustrating how the mevalonate pathway can be directly or indirectly modulated by many oncogenic pathways.
Several other common oncogenic events can regulate the mevalonate pathway. As previously discussed, the SREBP family of transcription factors are central to regulation of cholesterol and fatty-acid synthesis genes. 27 Increased transcriptional activity of SREBPs is reportedly activated by increased PI3K and AKT signalling, 132 frequent events in oncogenesis. 133 Activation of these oncogenic signalling cascades would in turn lead to an increased output of the mevalonate pathway.
Decreased adenosine monophosphate-activated protein kinase (AMPK) activation is believed to promote tumorigenesis, and the pharmacological activation of AMPK has been demonstrated to be cytotoxic to tumor cells. 134 The mevalonate pathway is also regulated by the activity of AMPK, which can phosphorylate HMGCR 135 and the SREBPs 136 to inhibit their activity. It is therefore also possible that the anticancer effects of AMPK activation and the tumor suppressor activity of its upstream kinase, liver kinase B1 (LKB1), are at least partially due to inhibition of HMGCR and the mevalonate pathway.
Tumor cell metabolism is regulated by the mevalonate pathway The isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate are key end products of the mevalonate pathway used to post-translationally modify proteins with C-terminal CAAX, CXC or CC motifs. 137 This process, called isoprenylation, is essential for proper localization and function of the RAS superfamily of small guanosine triphosphatases (GTPases), which have very wellestablished roles in cancer etiology and progression. 138 Though activated RAS has been linked to cellular glucose transport, its role in tumor cell metabolism has also been shown to be more complex. For example, activating mutation rates of RAS have been shown to be higher in colon cancer cells deprived of glucose, thereby driving glucose import via the glucose transporter 1. 139 Activation of KRAS has also been shown to be the final step of a multi-gene transformation process initiated by viral oncogenes and telomerase reverse transcriptase in human breast epithelial cells. 140 The transformed cells in this system rapidly convert glucose into lactate in a manner that is highly reminiscent of the Warburg phenomenon. Finally, RAS is also thought to regulate MYC activity and increase levels of HIF-1, independent of hypoxia.
--143
The PI3K and RAS signalling pathways converge at the tuberous sclerosis complex, made up of the TSC1 and TSC2 tumor suppressors, and a small GTPase called Rheb, 144 which is required for activation of mammalian target of rapamycin complex 1 (mTORC1) activity. 145 Activation of PI3K or RAS pathways can feed into aberrantly active mTORC1 activity. Such aberrant mTORC1 signalling occurs in 40 --90% of the 10 most frequent human cancers. 146 Furthermore, the LKB1 tumor suppressor, which is mutated in a number of cancers, is required for AMPK activation in response to energetic stress, also leading to abnormal mTORC1 signalling. 147 As a point in which numerous oncogene and tumor suppressor pathways overlap, mTORC1 controls a broad range of cellular processes common to all tumor cells.
CDC42, RAC and RHOA are known to be important in a number of biological processes, including cytoskeletal rearrangements to cell polarity, migration and cell cycle progression. 148 The RHO family has also been linked to cancer, as their deregulated activation can drive transformation 149, 150 and their overexpression has been noted in several human tumors. 151 --157 Furthermore, RHOA and RHOC are believed to have a role in metastasis. 158 --161 Most recently, the RHO GTPases have been linked to tumor metabolism through activation of glutaminase, which catalyzes the conversion of glutamine to glutamate and ammonia, a key step in glutamine metabolism 162 and contributor to the Warburg phenomenon. 119 As these small GTPases require isoprenylation to function properly, their activity is fundamentally dependent on HMGCR, thus providing additional links between the mevalonate pathway and tumor cell metabolism. Notably, it has been shown that disruption of any one isoprenylated protein, including RAS and RHO, is unlikely to mediate the anticancer activity of statins alone. 36, 163 This suggests that statin-induced apoptosis depends upon the loss of multiple isoprenylated proteins.
TRANSLATING STATINS TO CLINICAL ANTICANCER USE
Optimizing efficacy of statins as anticancer agents We believe statins have untapped potential as anticancer agents. This optimism is based on several factors: some successes in the clinical setting, continued epidemiological support, a new appreciation for the importance of HMGCR and the mevalonate pathway in oncogenesis, and recent work toward the identification of biomarkers of statin-sensitivity. To successfully advance statins as anticancer agents, we believe it will be critical to develop a sound rationale in designing clinical trials.
Seeking statin-sensitive tumors and subsets It will be of great value to accurately identify those patients who would benefit most from the addition of statins to their anticancer regimens. As described previously, we recently provided evidence that dysregulation of HMGCR and the mevalonate pathway may render multiple myeloma sensitive to the anticancer activity of statins. 39 It is our hope that this phenomenon can be translated into an experimentally tractable biomarker. Whether this biomarker can ultimately be applied to all tumor types universally remains to be seen, but hints of HMGCR deregulation in multiple different tumor types is supportive of that possibility. 103, 113, 114 It is likely that biomarkers of statin-sensitivity uncovered in other tumor types will assist in focusing clinical trials specifically on statin-sensitive tumors.
Not all statins are created equal In recent years, the statin family has expanded to include seven unique compounds that are either naturally derived (pravastatin, simvastatin and lovastatin) or chemically synthesized (fluvastatin, atorvastatin, rosuvastatin and pitavastatin). 164 --171 Statins are very effective competitive inhibitors as they bind to HMGCR approximately 1000-fold more tightly than the natural substrate. 172, 173 Statin-binding affinities to HMGCR (K i ) range from 0.1 to 2.3 nM, 166, 168, 171, 173 whereas the K m of HMG-CoA is only 4 mM.
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The pharmacokinetics of statins are variable and depend on the lipophilicity of the statin, whether it is in acid or lactone form, and the enzymes involved in their metabolism. 175 Despite the differences between statins, they have largely been used interchangeably. For cholesterol-lowering purposes, several studies have suggested that any appreciable differences in statin efficacy are merely mediated by how tightly they bind HMGCR and inhibit its activity. 176 --178 Early cell culture analyses of the anticancer activity of statins also indicated that statin efficacy was primarily dependent on how well they inhibit HMGCR. 179, 180 In practice, however, there appears to be variability that remains unaccounted for.
Most of the current evidence suggests that lipophilic statins may be preferable as anticancer agents for their ability to permeate the cell membrane and affect cell proliferation. 80 --82,181 --183 For example, lipophilic statin use after breast cancer diagnosis was associated with decreased risk of recurrence. 81, 82 A perioperative window trial with lipophilic fluvastatin showed that statin treatment resulted in decreased tumor proliferation and increased apoptosis in high-grade, early stage breast cancer. 61 Overall, these recent studies indicate that lipophilic statins may be most effective in an anticancer setting. Lipophilic statins as a class have been shown to remain in circulation longer and at higher plasma concentrations, despite a lower bioavailability and a greater degree of plasma protein binding. 184, 185 It is worth noting, however, that two of the most successful anticancer statin trials to date were conducted in hepatocellular carcinoma patients treated with pravastatin, a hydrophilic statin. 57, 69 The success of a hydrophilic statin in this case may in fact be because of their hepatoselective nature. This suggests that different statins may be better suited for treating some tumors but not others and that they should be deliberately chosen based upon distinct characteristics.
Finally, there are likely a host of molecular features that also contribute to differences in the anticancer potential of various statins, some of which would be considered off-target effects. One such effect that has recently been addressed is their capacity to interact with P-glycoprotein, a common multidrug transporter. 186, 187 Strikingly, both lovastatin and atorvastatin interacted directly with P-glycoprotein in vitro and lovastatin also modulated multidrug resistance in tumor cells. Rosuvastatin and fluvastatin, by contrast, did not interact with P-glycoprotein at biologically relevant concentrations and did not impact tumor cell multidrug resistance. It will clearly be significant to consider these types of factors when integrating statins into combination regimens.
Anticancer combinations with statins Lastly, it should be noted that statins would generally be combined with other treatment modalities in an anticancer setting. Treatment regimens for most cancers comprise multimodal approaches that often include a cocktail of drugs in addition to radiation and surgery. The strategy behind such combinations is to target the multiple deregulated pathways that a tumor depends on for its continued growth and survival. It is therefore desirable to combine statins with therapies that result in the potentiation of their combined anticancer activities.
Beyond drug interactions at the level of metabolism and drug resistance, cumulative evidence from clinical trials evaluating the anticancer activity of statins demonstrates that combination therapies maximize efficacy. 56, 57, 62, 64, 65 An appraisal of the many combinations that have been made with statins in vitro and in vivo have been extensively discussed elsewhere. 53 Notably, the majority of preclinical work to date has focused on combining statins with more traditional cytotoxic agents, ranging from anthracyclines 188, 189 to antimetabolites. 190, 191 This has translated to some clinical efficacy as well. For example, a statin added to a regimen of idarubicin and high doses cytarabine in a phase I study of AML patients yielded encouraging response rates in the absence of additional toxicity. 57 In a small phase II study of multiple myeloma patients, a statin was combined with standard vincristine, adriamycin and dexamethosone chemotherapy. 62 Though the study was ended early, there was promising evidence of increased efficacy with the statin combination. Finally, randomized controlled trials have also conducted in advanced hepatocellular carcinoma patients. Patients were treated with either transcatheter arterial embolization and oral 5-flurouracil 56 or transarterial chemoembolization, 69 both in the presence or absence of statin therapy. Remarkably, statin treatment approximately doubled the survival time of these patients in both trials.
Statins have also been evaluated for their capacity to augment ionizing radiation therapy. Indeed, a promising broadening of the therapeutic index has recently been suggested. Having been known to sensitize cancer cells to ionizing radiation-induced apoptosis, 192 additional work now suggests that statins also ameliorate the effect of ionizing radiation on normal tissues. 193 --196 Furthermore, a recent report indicated that statin use was strongly associated with pathological complete response to neoadjuvant chemoradiation for rectal cancer. 197 A role for statins in the radiotherapy of cancer is certainly indicated but it remains to be seen which tumor types would be most sensitive to such a combination.
It is clear that identifying optimal combinatorial regimens represents a critical step toward the anticancer success of statins.
CONCLUSION
Originally developed to address the escalating problem of high cholesterol in cardiovascular disease, statins appear to have extensive untapped potential. Though we have focused on the anticancer activity of statins, they have also exhibited a number of other pleiotropic effects. While some of these effects are related to cardiovascular health, others appear to be independent, ranging between effects on inflammation, to multiple sclerosis, Alzheimer's disease and bone density. 198 --207 The work reviewed here, however, indicates that statins are poised to deliver on their promise as anticancer agents. The substantial overlap between essential mevalonate pathway-dependent functions and many processes involved in tumor cell metabolism and oncogenesis shine new light on how these drugs may exhibit tumor-selective anticancer activity. A better molecular understanding of how and why a tumor is dependent on the mevalonate pathway will ultimately allow us to successfully exploit statins as anticancer agents. Furthermore, design of clinical trials moving forward should select for a subset of patients with statin-sensitive tumor characteristics and include a deliberately chosen statin in a rationally devised combinatorial regimen. In this manner, we will be readily able to elucidate the potential impact of anticancer statin therapy and make a greater contribution to patient care.
